Cargando…
Prostate Cancer Metastasis to the Pituitary Gland Manifesting as Corticosteroid Withdrawal, and the Impact of the Switch from Prednisone to Dexamethasone on Survival Time
Despite improvements in the diagnosis and treatment of cancers, the incidence of pituitary metastasis has increased. Prostate cancer metastasis to the pituitary, however, is rare, and these tumors usually grow rapidly. They are also more likely to be located in the posterior pituitary, and the prese...
Autores principales: | Ataikiru, Okeroghene, Abdelsalam, Mahmoud, Avileli, Mrudula, Hynes, Trina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628707/ https://www.ncbi.nlm.nih.gov/pubmed/34898537 http://dx.doi.org/10.3390/curroncol28060365 |
Ejemplares similares
-
Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
por: Yang, Zhenyu, et al.
Publicado: (2021) -
Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer
por: Ni, Yu-Chao, et al.
Publicado: (2021) -
Phase II pilot study of the prednisone to dexamethasone
switch in metastatic castration-resistant prostate cancer (mCRPC) patients with
limited progression on abiraterone plus prednisone (SWITCH study)
por: Romero-Laorden, Nuria, et al.
Publicado: (2018) -
Dexamethasone/prednisone: Acute pancreatitis: case report
Publicado: (2021) -
Dexamethasone/prednisone/tocilizumab: Worsening of Strongyloides infection: case report
Publicado: (2020)